Benzinga | Sep 15, 2020 11:43AM EDT

RBC Capital Maintains Outperform on Seattle Genetics, Raises Price Target to $191

RBC Capital analyst Kennen MacKay maintains Seattle Genetics (NASDAQ:SGEN) with a Outperform and raises the price target from $175 to $191.